vs
Side-by-side financial comparison of Hologic (HOLX) and StepStone Group Inc. (STEP). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $586.5M, roughly 1.8× StepStone Group Inc.). Hologic runs the higher net margin — 17.1% vs -21.0%, a 38.1% gap on every dollar of revenue. On growth, StepStone Group Inc. posted the faster year-over-year revenue change (73.0% vs 2.5%). Hologic produced more free cash flow last quarter ($215.2M vs $26.7M). Over the past eight quarters, StepStone Group Inc.'s revenue compounded faster (28.2% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Rosetta Stone Inc. is an American education technology software company that develops language, literacy and brain-fitness software. Best known for its language-learning products, in 2013, the company expanded beyond language into education-technology with its acquisitions of Livemocha, Lexia Learning, Fit Brains, and Tell Me More. In 2021, it became a subsidiary of IXL Learning.
HOLX vs STEP — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $586.5M |
| Net Profit | $179.1M | $-123.5M |
| Gross Margin | 56.0% | — |
| Operating Margin | 22.6% | -33.2% |
| Net Margin | 17.1% | -21.0% |
| Revenue YoY | 2.5% | 73.0% |
| Net Profit YoY | -10.9% | 35.7% |
| EPS (diluted) | $0.79 | $-1.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $586.5M | ||
| Q3 25 | $1.0B | $454.2M | ||
| Q2 25 | $1.0B | $364.3M | ||
| Q1 25 | $1.0B | $377.7M | ||
| Q4 24 | $1.0B | $339.0M | ||
| Q3 24 | $988.0M | $271.7M | ||
| Q2 24 | $1.0B | $186.4M | ||
| Q1 24 | $1.0B | $356.8M |
| Q4 25 | $179.1M | $-123.5M | ||
| Q3 25 | $187.2M | $-366.1M | ||
| Q2 25 | $194.9M | $-38.4M | ||
| Q1 25 | $-17.4M | $-18.5M | ||
| Q4 24 | $201.0M | $-192.0M | ||
| Q3 24 | $178.6M | $17.6M | ||
| Q2 24 | $194.5M | $13.3M | ||
| Q1 24 | $169.9M | $30.8M |
| Q4 25 | 56.0% | — | ||
| Q3 25 | 55.6% | — | ||
| Q2 25 | 56.3% | — | ||
| Q1 25 | 37.5% | — | ||
| Q4 24 | 56.8% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 55.4% | — | ||
| Q1 24 | 53.3% | — |
| Q4 25 | 22.6% | -33.2% | ||
| Q3 25 | 22.6% | -148.8% | ||
| Q2 25 | 24.9% | -5.6% | ||
| Q1 25 | -0.7% | 2.6% | ||
| Q4 24 | 22.5% | -101.7% | ||
| Q3 24 | 23.3% | 21.3% | ||
| Q2 24 | 24.1% | 29.4% | ||
| Q1 24 | 20.7% | 26.5% |
| Q4 25 | 17.1% | -21.0% | ||
| Q3 25 | 17.8% | -80.6% | ||
| Q2 25 | 19.0% | -10.5% | ||
| Q1 25 | -1.7% | -4.9% | ||
| Q4 24 | 19.7% | -56.6% | ||
| Q3 24 | 18.1% | 6.5% | ||
| Q2 24 | 19.2% | 7.2% | ||
| Q1 24 | 16.7% | 8.6% |
| Q4 25 | $0.79 | $-1.55 | ||
| Q3 25 | $0.84 | $-4.66 | ||
| Q2 25 | $0.86 | $-0.49 | ||
| Q1 25 | $-0.08 | $-0.37 | ||
| Q4 24 | $0.87 | $-2.61 | ||
| Q3 24 | $0.75 | $0.26 | ||
| Q2 24 | $0.82 | $0.20 | ||
| Q1 24 | $0.72 | $0.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | — |
| Total DebtLower is stronger | $2.5B | $270.2M |
| Stockholders' EquityBook value | $5.2B | $-378.8M |
| Total Assets | $9.2B | $5.2B |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.2B | — |
| Q4 25 | $2.5B | $270.2M | ||
| Q3 25 | $2.5B | $269.9M | ||
| Q2 25 | $2.5B | $269.6M | ||
| Q1 25 | $2.5B | $269.3M | ||
| Q4 24 | $2.5B | $168.9M | ||
| Q3 24 | $2.5B | $172.3M | ||
| Q2 24 | $2.5B | $172.1M | ||
| Q1 24 | $2.6B | $148.8M |
| Q4 25 | $5.2B | $-378.8M | ||
| Q3 25 | $5.0B | $-233.5M | ||
| Q2 25 | $4.8B | $153.9M | ||
| Q1 25 | $4.6B | $179.4M | ||
| Q4 24 | $4.8B | $209.8M | ||
| Q3 24 | $5.1B | $397.5M | ||
| Q2 24 | $5.0B | $366.9M | ||
| Q1 24 | $4.8B | $324.5M |
| Q4 25 | $9.2B | $5.2B | ||
| Q3 25 | $9.0B | $5.3B | ||
| Q2 25 | $8.8B | $4.8B | ||
| Q1 25 | $8.5B | $4.6B | ||
| Q4 24 | $8.7B | $4.3B | ||
| Q3 24 | $9.2B | $4.0B | ||
| Q2 24 | $8.9B | $3.8B | ||
| Q1 24 | $8.7B | $3.8B |
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | 1.75× | ||
| Q1 25 | 0.55× | 1.50× | ||
| Q4 24 | 0.53× | 0.81× | ||
| Q3 24 | 0.49× | 0.43× | ||
| Q2 24 | 0.51× | 0.47× | ||
| Q1 24 | 0.53× | 0.46× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $27.2M |
| Free Cash FlowOCF − Capex | $215.2M | $26.7M |
| FCF MarginFCF / Revenue | 20.5% | 4.6% |
| Capex IntensityCapex / Revenue | 1.4% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.28× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $18.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | $27.2M | ||
| Q3 25 | $355.1M | $16.2M | ||
| Q2 25 | $343.3M | $46.3M | ||
| Q1 25 | $169.4M | $-66.5M | ||
| Q4 24 | $189.3M | $27.6M | ||
| Q3 24 | $367.0M | $53.7M | ||
| Q2 24 | $405.8M | $50.2M | ||
| Q1 24 | $292.4M | $7.6M |
| Q4 25 | $215.2M | $26.7M | ||
| Q3 25 | $341.4M | $15.9M | ||
| Q2 25 | $330.5M | $45.2M | ||
| Q1 25 | $153.9M | $-69.2M | ||
| Q4 24 | $172.5M | $27.0M | ||
| Q3 24 | $350.6M | $52.4M | ||
| Q2 24 | $385.3M | $49.6M | ||
| Q1 24 | $279.6M | $6.7M |
| Q4 25 | 20.5% | 4.6% | ||
| Q3 25 | 32.5% | 3.5% | ||
| Q2 25 | 32.3% | 12.4% | ||
| Q1 25 | 15.3% | -18.3% | ||
| Q4 24 | 16.9% | 8.0% | ||
| Q3 24 | 35.5% | 19.3% | ||
| Q2 24 | 38.1% | 26.6% | ||
| Q1 24 | 27.5% | 1.9% |
| Q4 25 | 1.4% | 0.1% | ||
| Q3 25 | 1.3% | 0.1% | ||
| Q2 25 | 1.3% | 0.3% | ||
| Q1 25 | 1.5% | 0.7% | ||
| Q4 24 | 1.6% | 0.2% | ||
| Q3 24 | 1.7% | 0.5% | ||
| Q2 24 | 2.0% | 0.3% | ||
| Q1 24 | 1.3% | 0.3% |
| Q4 25 | 1.28× | — | ||
| Q3 25 | 1.90× | — | ||
| Q2 25 | 1.76× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.05× | 3.05× | ||
| Q2 24 | 2.09× | 3.76× | ||
| Q1 24 | 1.72× | 0.25× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
STEP
| Other | $210.1M | 36% |
| Management And Advisory Fees Net Focused Commingled Funds | $143.3M | 24% |
| Carried Interest Allocation Focused Commingled Funds | $85.1M | 15% |
| Carried Interest Allocation Separately Managed Accounts | $63.6M | 11% |
| Carried Interest Allocation Realized | $46.7M | 8% |
| Management And Advisory Fees Net Advisory And Other Services | $18.3M | 3% |
| Legacy Carried Interest Allocation Focused Commingled Funds | $10.3M | 2% |
| Income Based Incentive Fees | $6.0M | 1% |
| Management And Advisory Fees Net Fund Reimbursement Revenues | $3.1M | 1% |
